Once‐Weekly Exenatide: An Extended‐Duration Glucagon‐Like Peptide Agonist for the Treatment of Type 2 Diabetes Mellitus

Apr 5, 2013Pharmacotherapy

Once-weekly exenatide as a long-lasting treatment for type 2 diabetes

AI simplified

Abstract

Once-weekly exenatide is a 2-mg injection that may improve hemoglobin A1c levels and result in weight loss.

  • Exenatide is an extended-duration glucagon-like peptide-1 (GLP-1) agonist administered once every 7 days.
  • It has pharmacotherapeutic effects that are superior to twice-daily exenatide and sitagliptin, and comparable to insulin glargine.
  • Adverse effects include gastrointestinal issues, hypoglycemia, injection-site reactions, pancreatitis, and antibody development.
  • Patients with a personal or family history of thyroid tumors should not use once-weekly exenatide.
  • Monitoring is necessary to prevent delays in gastric absorption when taken with orally administered drugs.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free